Piramal Pharma Ltd (NSE:PPLPHARMA)

Q1 2027 Piramal Pharma Ltd (Mumbai) Earnings Call Transcript

Jul 29, 2026 / 04:00 AM GMT

Release Date Price: ₹196.72 (+0.53%)

Transcript

Key Points

Positve

Piramal Pharma Ltd (BOM:543635) reported a strong start to FY27 with revenue from operations growing 17% year-on-year to 2,270 crores and EBITDA increasing 72% to 285 crores, with margins expanding by approximately 400 basis points to 12.5%.
The CDMO business delivered 19% year-on-year revenue growth, driven by broad-based growth across India and overseas sites, supported by strong execution, improved demand conditions, and a meaningful increase in RFP activity.
The company is strengthening its differentiated capabilities, particularly in the ADC space, with the inauguration of a new commercial-scale payload linker development manufacturing site at Riverview and the expansion of sterile injectable capacity at Lexington, part of a US $90 million expansion program.
The Complex Hospital Generics business delivered a resilient performance with 17% year-on-year revenue growth, maintaining leadership positions in key therapies like sevoflurane (48% US market share) and intrathecal baclofen, while expanding in ex-US markets.
The Consumer Healthcare business continued its strong momentum with mid-teen revenue growth, driven by power brands growing 23% year-on-year and e-commerce growing 40% year-on-year, contributing 28% of sales.
The company received an EIR from the US FDA for its Sellersville facility, successfully concluding the inspection and maintaining a zero OAI classification across its global network.
Piramal Pharma Ltd (BOM:543635) announced strategic collaborations with Agenomoto Biopharma Services for ADC technology and a manufacturing and supply agreement with Botanics, highlighting the strength of its integrated North American network.
The company's Net Promoter Score (NPS) has improved to around 60%, which is significantly higher than the industry average, indicating high customer satisfaction and leading to new business wins and referrals.

Negative

The company's effective tax rate remains elevated due to higher incidence of profit in tax-paying jurisdictions and a disallowance on R&D tax credits, with management guiding that tax rates will remain elevated for the current financial year.
Customer decision-making timelines in the CDMO business remain extended, which could impact the timing of order conversions and revenue recognition.
The Complex Hospital Generics business continues to face competitive pressure from Chinese competition, although the company's actions have started to bear fruit.
The company's overseas subsidiaries are not yet at scale, resulting in lower PBT and an inflated effective tax rate, with a gradual shift expected as utilization levels improve.
The large contract that had seen destocking is not anticipated to contribute any sales in the current fiscal year (FY27), with the company continually in touch with the innovator but no material change expected.
Gross margins at the subsidiary level showed a decline year-on-year (from 72% to 68%), although management attributes this to quarterly mix impacts and not indicative of the annual trend.
The company faces ongoing inflationary pressures, which it is mitigating through pricing discipline and operational excellence initiatives, but these remain a challenge.
Management declined to provide specific guidance on the revenue potential of the new ADC facility or the late-stage pipeline molecules, citing that these are updated annually, which may limit investor visibility.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PIRM.NS - Piramal Pharma Ltd (Mumbai)
Q1 2027 Piramal Pharma Ltd (Mumbai) Earnings Call
Jul 30, 2026 / 04:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Peramal Pharma Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during this conference call, please signal an operator by pressing then 0 on your touch tone phone.

Please note this conference is being recorded.

At this time, I would like to hand the conference over to Mr. Kagan, Head of Investor Relations and Enterprises Risk Management.

Thank you, and over to you, sir.

------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.